Potential Alzheimer's Therapies Focus on Early Intervention

Disclosures from H. C. Wainwright & Co., Industry Update, "Focusing on Early Intervention: New Learnings and Key

Insights From the 10th Clinical Trials on Alzheimer’s Disease," Nov. 27, 2017

I, Andrew S. Fein and Li Wang Watsek , certify that 1) all of the views expressed in this report accurately reflect my personal

views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly

or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any

members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Biogen, Inc

(including, without limitation, any option, right, warrant, future, long or short position).

As of October 31, 2017 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities

of Biogen, Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has

reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any

specific investment banking services or transaction but is compensated based on factors including total revenue and profitability

of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from Biogen, Inc for investment banking services within twelve months

before, but will seek compensation from the companies mentioned in this report for investment banking services within three

months following publication of the research report.

The Firm does not make a market in Biogen, Inc as of the date of this research report.